Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00161954
Status:
COMPLETED
Last Update Posted:
2015-05-21
First Post:
2005-09-08
Brief Title:
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 05 mL in Healthy Adults Aged 16 - 65 Years
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 05 mL in Healthy Adults Aged 16 - 65 Years
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 05 mL using a rapid immunization schedule 2 vaccinations administered 12 - 2 days apart
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None